Scots say yes to BMS/Pfizer's Eliquis and BI's Trajenta
This article was originally published in Scrip
Scotland's health technology appraisal body, the Scottish Medicines Consortium, has given the green light to Bristol-Myers Squibb/Pfizer's Eliquis (apixaban) for stroke prevention and Boehringer Ingelheim's Trajenta (linagliptin) for improving glyecamic control in type 2 diabetes patients.
You may also be interested in...
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.